Hikma Pharmaceuticals Public annual revenue
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Revenue Growth & History (HIK)
Hikma Pharmaceuticals Public reported $3.35B in revenue for fiscal 2025, an increase of 7.10% from the previous fiscal year.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.35B | $222.0M | +7.10% |
| 2024 | 2024-12-31 | $3.13B | $252.0M | +8.77% |
| 2023 | 2023-12-31 | $2.88B | $358.0M | +14.22% |
| 2022 | 2022-12-31 | $2.52B | −$36.0M | −1.41% |
| 2021 | 2021-12-31 | $2.55B | $212.0M | +9.06% |
| 2020 | 2020-12-31 | $2.34B | — | — |
Hikma Pharmaceuticals Public revenue growth trends
Over the last five reported fiscal years, revenue grew from $2.34B to $3.35B, a compound annual growth rate of 7.42%.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...